Mason & Associates (California)’s Biogen BIIB Stock Holding History

Mason & Associates (California)’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$224K	Buy	+1,038	New	+$199K	0.04%	157
2025 Q4	–	Sell	-1,563	Closed	-$219K	–	159
2025 Q3	$219K	Buy	+1,563	New	+$211K	0.04%	125
2024 Q3	–	Sell	-1,028	Closed	-$238K	–	111
2024 Q2	$238K	Hold	1,028	–	–	0.06%	97
2024 Q1	$222K	Hold	1,028	–	–	0.06%	103
2023 Q4	$266K	Buy	1,028 +15	+1%	+$3.68K	0.08%	73
2023 Q3	$260K	Hold	1,013	–	–	0.08%	71
2023 Q2	$289K	Hold	1,013	–	–	0.09%	70
2023 Q1	$282K	Hold	1,013	–	–	0.09%	68
2022 Q4	$281K	Hold	1,013	–	–	0.09%	63
2022 Q3	$270K	Hold	1,013	–	–	0.1%	67
2022 Q2	$207K	Hold	1,013	–	–	0.07%	83
2022 Q1	$213K	Hold	1,013	–	–	0.07%	106
2021 Q4	$243K	Buy	+1,013	New	+$260K	0.07%	87

Other funds holding BIIB

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

ECSS

Eurizon Capital SGR SpA Milan $37.3B AUM

ADEF

Adams Diversified Equity Fund Baltimore, Maryland $3.27B AUM 45.57% 1-Year Est. Return

Mason & Associates (California)'s BIIB Position: Q2 2026 in Review

Mason & Associates (California) opened a new position in Biogen (BIIB) in Q2 2026: 1,038 shares worth $224K. The stake represents 0.04% of the portfolio and ranks #157 among its holdings. This is a return to the name: Mason & Associates (California) previously reported a position in BIIB as recently as Q3 2025.

Mason & Associates (California) first reported a position in BIIB in Q4 2021 and has held it in 13 quarters since. The position peaked at $289K in Q2 2023. 405 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Mason & Associates (California) held 1,038 shares of Biogen worth $224K as of Q2 2026.
Biogen was a new Mason & Associates (California) position in Q2 2026.
Biogen made up 0.04% of Mason & Associates (California)'s portfolio in Q2 2026, its #157 holding.
Mason & Associates (California) first reported a position in Biogen in Q4 2021 and has held it in 13 quarters since.
Mason & Associates (California)'s Biogen position peaked at $289K in Q2 2023.
405 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Mason & Associates (California)'s 13F filing for Q2 2026, filed 23 Jul 2026.